newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

  • Cogent Biosciences submitted a New Drug Application (NDA) for bezuclastinib in imatinib-resistant GIST patients to the FDA under the Real-Time Oncology Review (RTOR) program.
  • The NDA submission is based on positive Phase 3 PEAK trial results & bezuclastinib previously received Breakthrough Therapy Designation for GIST.
  • In the PEAK trial, the bezuclastinib & sunitinib combination demonstrated a 16.5-month median progression-free survival (mPFS) compared to 9.2 months for sunitinib monotherapy.
  • The combination achieved a 46% objective response rate (ORR) in imatinib-resistant patients, surpassing the 26% rate for sunitinib monotherapy.
  • The trial data showed a 50% reduction in the risk of disease progression or death (hazard ratio of 0.50) compared to the current standard of care.
  • No unique safety risks were observed with the bezuclastinib & sunitinib combination relative to the known safety profile of sunitinib.
  • Cogent plans to present full PEAK trial results at a major medical meeting during the first half of 2026.
  • A Phase 2 trial investigating bezuclastinib & sunitinib for first-line GIST patients with exon 9 mutations is scheduled to initiate this quarter.
  • An NDA submission for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) is on track for the first half of 2026.
  • Active Expanded Access Programs (EAPs) are available for U.S. patients with GIST or Systemic Mastocytosis who meet specific criteria.
  • On March 30, 2026, the Board of Directors approved inducement equity grants to six new employees under Nasdaq Listing Rule 5635(c)(4).
  • The approved inducement awards included nonqualified options to purchase 21,100 shares & 15,700 restricted stock units (RSUs) with 4-year vesting schedules.